key: cord-1056233-fym3yqdz authors: Sattui, Sebastian Eduardo; Liew, Jean W; Kennedy, Kevin; Sirotich, Emily; Putman, Michael; Moni, Tarin T; Akpabio, Akpabio; Alpízar-Rodríguez, Deshiré; Berenbaum, Francis; Bulina, Inita; Conway, Richard; Singh, Aman Dev; Duff, Eimear; Durrant, Karen L; Gheita, Tamer A; Hill, Catherine L; Howard, Richard A; Hoyer, Bimba F; Hsieh, Evelyn; El Kibbi, Lina; Kilian, Adam; Kim, Alfred Hyoungju; Liew, David F L; Lo, Chieh; Miller, Bruce; Mingolla, Serena; Nudel, Michal; Palmerlee, Candace A; Singh, Jasvinder A; Singh, Namrata; Ugarte-Gil, Manuel Francisco; Wallace, John; Young, Kristen J; Bhana, Suleman; Costello, Wendy; Grainger, Rebecca; Machado, Pedro M; Robinson, Philip C; Sufka, Paul; Wallace, Zachary S; Yazdany, Jinoos; Harrison, Carly; Larché, Maggie; Levine, Mitchell; Foster, Gary; Thabane, Lehana; Rider, Lisa G; Hausmann, Jonathan S; Simard, Julia F; Sparks, Jeffrey A title: Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey date: 2021-09-07 journal: RMD Open DOI: 10.1136/rmdopen-2021-001814 sha: a1485df04791003952931879eb8a544c9cc3b067 doc_id: 1056233 cord_uid: fym3yqdz BACKGROUND: We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. METHODS: From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. RESULTS: We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. CONCLUSION: Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring. ► People with systemic rheumatic diseases, who were largely excluded from COVID-19 vaccine clinical trials, may have additional concerns about the impact of their underlying disease or antirheumatic medications on COVID-19 vaccine response. ► Studies of rheumatic disease flares following vaccination for other infections were previously reassuring, and studies from a physician-based registry and a prospective cohort have shown a low frequency of flares following COVID-19 vaccination. What does this study add? ► In this international online survey of adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population, with rheumatic disease flare requiring medication changes occurring in <5%. ► Most patients were willing to temporarily discontinue disease-modifying antirheumatic drugs in order to improve vaccine efficacy. Multiple COVID-19 vaccines have become available, with established safety and efficacy in the general population. 1 However, people with systemic rheumatic diseases, who may have a unique risk and benefit profile, were largely excluded from the initial vaccine clinical trials. People with systemic rheumatic diseases may have specific concerns on how their underlying disease or their immunomodulatory therapies affect the benefit and safety of receiving COVID-19 vaccination. 2 3 These concerns have been further complicated by heterogenous vaccine rollouts and access, and conflicting advice from clinicians in response to major organisation recommendations. [4] [5] [6] There is a paucity of data regarding vaccinated patients with rheumatic diseases, and better information could inform decision making and guidance for clinicians and patients. This study describes a large, international survey of adults with systemic rheumatic disease who received a COVID-19 vaccine, focusing on their experiences communicating with clinicians, their beliefs about and management of medications for their rheumatic disease around the time of vaccination, and their experience with adverse events after vaccination. The COVID-19 Global Rheumatology Alliance (C19-GRA) Vaccine Survey was developed and refined based on feedback from relevant stakeholders (clinicians, researchers and patient partners) and collaborators from December 2020 through March 2021. The survey collected information from both COVID-19 vaccinated and unvaccinated adults with systemic rheumatic diseases. To study a more homogenous group and to obtain a better understanding of characteristics and factors associated with vaccination, this analysis was restricted to adults with systemic rheumatic diseases who received COVID-19 vaccination. Respondents were included if they completed the survey in English, Italian or Hebrew (first translations made available) between 2 April and 30 April 2021 and reported having received at least one dose of any COVID-19 vaccine. Respondents were excluded if they did not provide information on the following characteristics: age, sex, country of residence, race/ethnicity, rheumatic disease diagnosis and use of antirheumatic medications. Respondents reporting only diagnoses of osteoarthritis and/or only fibromyalgia without other systemic rheumatic diseases were also excluded. The survey was administered online using the Qualtrics platform, an online survey software that allows for the creation and distribution of surveys and other measurement tools. After providing initial consent to participate, respondents were required to enter their year of birth and only received additional questions if they were over the age of 18 years. Where possible, participants were required to enter a response to questions before proceeding in order to minimise missing responses. Also, Internet Protocol address gating, restricting only one survey entry per individual (or source), was employed in order to secure integrity of responses and data. Measures and data collection Demographics Self-reported demographics including year of birth (from which age was calculated), sex assigned at birth, highest level of education, current employment and country of residence were collected. Country of residence was grouped by the WHO region. 7 Race/Ethnicity was grouped into mutually exclusive categories: black, Asian (including East Asian, South Asian and West Asian), Hispanic, Latinx or Latin American, white, American Indian/Alaska Natives/Aboriginal/Indigenous/ First Nations, Arab, Pacific Islander and multiple identities (ie, participants reporting more than one race/ ethnicity). Participants could report multiple systemic rheumatic disease diagnoses. Comorbidities were also collected and included over 30 possible selections. Patient global assessment of current rheumatic disease activity was selfreported using a patient global assessment of disease activity visual analogue scale from 0 (remission/very low disease activity) to 10 (very high disease activity). 8 Disease-modifying antirheumatic drug, glucocorticoid and nonsteroidal anti-inflammatory drug use Participants reported the disease-modifying antirheumatic drugs (DMARDs), glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) that they were taking at the time of the survey. Medications were grouped into different classes according to mechanism of action, with a free text option to report additional medications. Free text was categorised into appropriate medication classes after translation. How might this impact on clinical practice or further developments? ► Clinicians should maintain awareness of changing guidelines as further data become available in order to provide continued communication and patient counselling regarding risks and benefits of vaccination. DMARDs were categorised using the most recent American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Summary. 6 Medications, where holding or altered dosage timing around time of vaccination was recommended (methotrexate, abatacept, rituximab, Janus kinase (JAK) inhibitors) were grouped independently. Participants were asked about vaccine-related communication and counselling by their clinicians. All survey respondents were asked about their general willingness to temporarily discontinue medications based on a 5-point Likert scale. In addition, for each specific medication that participants reported taking, they were asked if they would be willing to discontinue those medications (yes/no/unsure), to improve the effectiveness of a COVID-19 vaccine. They were also asked about their greatest concern(s) about temporarily discontinuing those medications. Finally, participants were asked if they held any medications before or after vaccination (yes/ no/unsure). In addition to self-reported anaphylaxis, participants were asked about the occurrence of postvaccination adverse events, lasting >2 days and within 2 months of vaccination, such as headaches, fever or chills, widespread muscle/ joint pain and rash, among others. Respondents also reported whether they experienced postvaccine flares of existing systemic rheumatic disease (lasting >2 days) and if these flares required treatment modifications. The English language version of the survey was launched globally on 2 April 2021. Translations in Italian and Hebrew were added on 5 April 2021. We employed a convenience sampling strategy with patient partners leading survey dissemination. International patient organisations received images, text and survey links designed to explain the survey's purpose, and disseminated the survey to their members. Additionally, the survey was publicly accessible from the C19-GRA website ( www. rheum-covid. org) and disseminated via social media by GRA members and patient organisations. The full survey is included in the online supplemental materials. Descriptive statistics, including means and SD, proportions and 95% CIs, were reported. All analyses were performed using R V.4.1.0. *Other participants include Pacific Islander, other, prefer not to say and do not know/unsure. †Participants may indicate more than one rheumatic disease and more than one antirheumatic medication. ‡Other connective tissue disease include mixed connective tissue disease and undifferentiated connective tissue disease. §Includes apremilast, azathioprine, 6-mercaptopurine, leflunomide, sulfasalazine. ¶Includes calcineurin inhibitors (ciclosporin, tacrolimus), cyclophosphamide, thalidomide and lenalidomide. **Includes asthma, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung disease, idiopathic pulmonary fibrosis, other lung diseases. † †Includes belimumab, IL-1 inhibitors (anakinra, canakinumab, rilonacept), IL-6 inhibitors (tocilizumab, sarilumab, siltuximab), IL-12/IL-23 inhibitors (ustekinumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab), eculizumab, mepolizumab and vedolizumab. ‡ ‡Includes Novavax, Sinovac/Sinopharm, Sputnik V, Cansino, 'not sure' and 'other'. bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, drug-modifying antirheumatic drugs; IL, interleukin; IVIG, intravenous immunoglobulin; JAK, Janus kinase inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor. When asked about the specific medications that participants reported taking for the treatment of their systemic rheumatic disease, the majority were willing to discontinue these medications due to COVID-19 vaccination (figure 2; online supplemental table). For participants taking methotrexate, 700/855 (81.9%) were willing to stop, with only 59 (6.9%) not willing to stop. For other medications recommended by the ACR to be modified around COVID-19 vaccination (eg, NSAIDs, mycophenolate, abatacept, rituximab, JAK inhibitors), the majority of respondents were willing to discontinue temporarily. Among participants taking systemic glucocorticoids, fewer (375/762, 49.2%) were willing to stop, 246 (32.3%) were not willing to stop and 141 (18.5%) were unsure. Finally, when asked about actual medication discontinuation, most patients who reported taking any prescription medication (1875/2644, 70.9%) answered that they did not temporarily stop or discontinue any of their rheumatic medications before or after receiving the COVID-19 vaccine, while a minority decided to change their medication use (764, 28.9%). Only five (0.2%) patients were not sure if they had made any changes to their medication use. Systemic rheumatic disease flare was the most frequently reported concern regarding holding or stopping antirheumatic medications (table 3) . In participants taking systemic glucocorticoids, disease flares were the most frequently reported concern (443/762, 58.1%) followed by withdrawal effects (188, 24.7%). Disease flare was the most common concern among patients on all other medications. 'No concerns' was the second most frequent response for people receiving all other medications, except for TNF inhibitors and other bDMARDs where 'concern for rheumatic medication may not work as well' (73/494, 14.8% and 21/206, 10.2%, respectively) was reported. People with systemic rheumatic disease represent a subgroup for whom general population data may not apply. Potential concerns include reduced immunogenicity of vaccines related to either the underlying condition or the use of antirheumatic medications; and vaccines causing worsened adverse events or flares of their underlying rheumatic diseases. 2 In an international survey of 1531 individuals with rheumatic disease conducted in December 2020, for instance, 32% reported uncertainty around vaccination, 3 which may in part be driven by these concerns. Rheumatologists have a prominent role in communicating risks and benefits of vaccination. Prior surveys of people with systemic rheumatic diseases have highlighted limited communication with rheumatologists or other healthcare providers, especially about medication changes. [9] [10] [11] Other studies have cited lack of a recommendation from a treating physician for vaccination hesitancy. [12] [13] [14] [15] Among the vaccinated population in our study, there was a high frequency of communication with clinicians about the COVID-19 vaccines, and respondents were generally very satisfied. A key factor is the timing of our survey during global vaccination efforts versus other surveys that were completed prior to the availability of the COVID-19 vaccine. Another factor is that our study sample was limited to those who were vaccinated, so good communication with healthcare providers over vaccine recommendations is unsurprising. Whether to hold antirheumatic medications for vaccination, and for how long, remains unclear for many medication classes. Hypothetical concerns about reduced immunogenicity have recently been corroborated by antibody titre studies. 16 17 Recommendations from the ACR, for instance, have reflected these concerns. Initial guidance in February of 2021 recommended holding methotrexate, JAK inhibitors, abatacept and rituximab in certain patients with controlled disease 6 ; an April 2021 update also included mycophenolate mofetil. 18 These guidelines were based on limited data, including one randomised controlled trial of methotrexate holding for influenza vaccination in patients with RA, 19 and two studies of holding tofacitinib in patients with RA. 20 Our survey found that most patients would be willing to temporarily discontinue their medications but had concerns about a flare of their systemic rheumatic disease. As expected, current glucocorticoid users had an especially high frequency of respondents who were less willing to hold these medications. This may be explained by prior experience of flares when stopping or lowering dose of glucocorticoids, concerns about adrenal insufficiency or a relationship between glucocorticoid use and active disease. However, despite reported willingness, only a minority of participants discontinued any medication around COVID-19 vaccination. Future studies are needed to firmly establish an evidence base for temporarily holding specific antirheumatic therapies to enhance vaccine efficacy while balancing risk for disease flare. The degree to which vaccination in general and the COVID-19 vaccinations in particular cause flares of rheumatic diseases has been a principal concern. 21 Prior to the COVID-19 pandemic, a study in the UK Clinical Practice Research Database found no increased risk of flare after influenza vaccination among people with autoimmune inflammatory rheumatic disease. 22 In a small study, RA disease activity remained stable following hepatitis B vaccination. 23 Conversely, an internet-based case-crossover study of patients with confirmed gout found twofold higher odds for gout flares after any patient-reported vaccination. 24 Similar to the rates reported in trials in the general population, a minority of patients in our study reported systemic reactions to vaccination, which included fatigue, fever and pain. Systemic rheumatic disease flares requiring a change in medication, however, were uncommon. These data align with a large, physicianreported registry supported by EULAR COVID-19 database. 25 Between 5 February and 27 April 2021, clinicians reported 1519 patients with rheumatic disease who had received COVID-19 vaccination, the majority (83%) of whom received an mRNA-based vaccine. Overall, 31% had potential vaccine-related side effects; 5% had flares of their underlying systemic rheumatic disease, 1.2% of which were reported as severe. In two prospective cohorts of patients with systemic rheumatic disease followed after COVID-19 vaccination, disease activity remained stable. 26 27 The complementary findings from these two studies provide reassuring evidence regarding safety and reactogenicity of COVID-19 vaccination among a systemic rheumatic disease population. Strengths of our study include rapid dissemination, global reach and questions specifically addressing concerns and willingness to hold specific antirheumatic medications. Several important limitations should be acknowledged. First, selection bias may have resulted from respondents with adverse events being more likely to fill out the survey. Despite this, the frequency of systemic rheumatic disease flares requiring medication changes remained low and was overall consistent with similar registries. Second, although participants were asked "Has a doctor ever told you had any of the following rheumatologic diseases?", report of self-diagnosis or misdiagnosis is a possibility. However, the reports of treatment with systemic immunomodulators prescribed by clinicians and the fact that the distribution of the survey through patient organisations potentially minimises this making it unlikely that this could substantially affect the results. Third, this study was limited to English, Hebrew and Italian translations of the survey and may not be generalisable to those who speak other languages or reside in other regions. Translations into other languages are ongoing and will be reported in the future. Fourth, respondents were mostly white and reported high levels of education. These results may not be applicable to addressing barriers among other racial or ethnic groups or among other socioeconomic groups. [28] [29] [30] Fifth, at the time of the survey, geographic variation in vaccine availability and access resulted in a preponderance of UK and US respondents. Sixth, the timing of our survey coincided with the Centers for Disease Control and Food and Drug Administration pause on the Janssen/Johnson & Johnson vaccine, [31] [32] [33] which limited the number of responses from those who had received this vaccine. Seventh, some conditions such as inflammatory myositis may be over-represented in our cohort, due to the registries and patient advocacy groups to which our survey was disseminated most easily. Finally, this was a descriptive analysis and inferential statistics were intentionally not performed. This study presents encouraging data regarding communication between people with systemic rheumatic diseases and their physicians and to the overall safety of COVID-19 vaccination in this patient population. Reassuringly, significant flares requiring changes in medications were relatively infrequent. Clinicians should maintain awareness of changing guidelines as further data become available to provide continued communication and patient counselling regarding risks and benefits of vaccination. Future studies should assess the degree to which vaccine immunogenicity and reactogenicity among individuals with systemic rheumatic disease differ compared with the general population. Further knowledge about barriers to vaccination in different racial and ethnic groups among patients living with systemic rheumatic diseases is needed. Disclaimer The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance and do not necessarily represent the views of the American College of Rheumatology (ACR), EULAR, the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR) or the (UK) Department of Health, or any other organisation. The funders had no role in the decision to publish or preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available on reasonable request. Researchers interested in performing additional analyses from survey data are invited to submit proposals through the COVID-19 Global Rheumatology Alliance at rheum-covid. org. For approved projects, we will be able to provide summary tables and data analyses as requested. We do not currently have IRB approval to make the raw data available to other researchers. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/. COVID-19 Vaccine Tracker Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases COVID-19 vaccinations. our world in data Canadian rheumatology association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1 Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-Joint counts (DAS28), simplified disease activity index (SDAI), Cl Self-Protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic Biologics, spondylitis and COVID-19 Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA) Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv2020 Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immunemediated inflammatory disease American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2 Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the clinical practice research Datalink Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis Risk of gout flares after vaccination: a prospective case cross-over study LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Latest data on COVID-19 vaccinations race/ethnicity. Kaiser family Foundation Factors associated with racial/ethnic group-based medical Mistrust and perspectives on COVID-19 vaccine trial participation and vaccine uptake in the US Racial and ethnic differences in COVID-19 COVID-19 vaccine use following thorough safety review CDC. CDC recommends use of Johnson & Johnson's Janssen COVID-19 vaccine FDA. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine Acknowledgements We would like to thank Saskya Angevare, Richard P Beesley, Eugenia Chock, Berk Degirmenci, Christele Felix, Shangyi Jin, Elsa Mateus, Andrea Peirce, Esra Sari, Robert Tseng, Leslie Wang and Erick Adrian Zamora for their invaluable contributions to the GRA Vaccine Survey.Competing interests SES has received funding from the Vasculitis Foundation and the Vasculitis Clinical Research Consortium unrelated to this work. JL has received research grant funding from Pfizer unrelated to this work. ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteerbased organisation whose activities are primarily supported by independent grants from pharmaceutical companies. MP was supported by a Rheumatology Research Foundation Scientist Development grant. DA-R is a Scientific Advisor for GlaxoSmithKilne unrelated to this work. FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma outside of the submitted work. No funding relevant to this manuscript. RC: speakers bureau for Janssen, Roche, Sanofi, AbbVie. KD reports no COI-unpaid volunteer president of the Autoinflammatory Alliance. Any grants or funding from pharma is received by the non-profit organisation only. CLH received funding under a sponsored research agreement unrelated to the data in the paper from Vifor Pharmaceuticals. LeK has received a research grant from Lilly unrelated to this work. AHJK participated in consulting, advisory board or speaker's bureau for Alexion Pharmaceuticals, Aurinia Pharmaceuticals, Annexon Biosciences, Exagen Diagnostics and GlaxoSmithKilne and received funding under a sponsored research agreement unrelated to the data in the paper from GlaxoSmithKline. JSingh has received consultant fees from Crealta/ Horizon MFU-G has received research support from Pfizer and Janssen, unrelated to this work. SB reports personal fees from Novartis, AbbVie, Pfizer and Horizon Pharma, outside the submitted work. RG reports personal fees from AbbVie New Zealand, Cornerstones, Janssen New Zealand and personal fees and non-financial support Pfizer New Zealand (all